rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
Status: Recruiting

The purpose of this study is to evaluate safety, tolerability, PK and immunogenicity of SV001 compare to placebo in Chinese healthy adult volunteers.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Subjects must fully understand the purpose, characteristics, methods and possible adverse reactions of the trial, volunteer as a subject, and sign the Informed Consent Form; Subjects must have a Body Mass Index in the range of 19~26 kg/m2, with males weighted not less than 50 kg, and females weighted not less than 45 kg; Subjects must be in good health as judged by the investigator. Reliable contraception must be assured during and for some time after the trial.  Exclusion Criteria:  Subjects with a history of drug or other substance anaphylaxis; Subjects with respiratory symptoms or abnormal respiratory tract; Subjects currently having an oral disease that the investigator judged may affect use of the trial drug and devices; Subjects with other diseases or factors with abnormal clinical manifestations; Subjects having a history of drug abuse in the past or having used narcotics in the period prior to screening, or having a positive result in urine narcotics test at baseline period; Subjects who smoked more than 5 cigarettes a day in the period before screening; Subjects who consumed more than 14 units of alcohol per week in the period prior to screening, or who is positive in breath alcohol test at baseline period; Subjects who have suffered a clinically significant severe disease or undergone major surgical operations within a certain period of time prior to receiving the investigational drug, or who are expected to require major operations during the clinical trial; Subjects who used other drugs within a certain period of time before receiving the investigational drug; Screening period: FEV1≤80% predicted value or FVC≤80% predicted value; Subjects who have antibody positive for Human Immunodeficiency Virus, Hepatitis B surface antigen, Hepatitis C or Treponema Pallidum. Subjects who have difficulty in venous blood collection or have a history of acupuncture syncope and blood phobia; Female subjects who are tested positive for pregnancy during the screening or baseline period or are in lactation period; Subjects who have participated in other drug clinical trials and used other drugs in clinical trials within a certain period of time before receiving the investigational drug; Subjects who have a history of blood donation or blood loss of more than 400 mL in the period prior to screening; Any other status in which the investigator deems inappropriate to participate in the present study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 45 Years - StdAgeList: Adult
A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer
Status: Not yet recruiting

This study collected data on patients with extensive stage small cell lung cancer treated with Adebrelimab to investigate its safety and efficacy

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Sign informed consent and join the study voluntarily; Patients diagnosed with extensive small cell lung cancer; Age ≥18 years old; Have at least one measurable lesion (according to RECIST 1.1); The investigators judged that adebrelimab treatment was acceptable; Contraception: Patients should agree that it must be used during the study period and within 6 months after the study ends Effective contraception;  Exclusion Criteria:  Allergic to adebrelimab and its excipients; Patients who have also received other immune drugs or therapies; Patients who are participating in other interventional studies; patients with other malignant tumors; Pregnant or lactating women; The investigator considers that the patient is not suitable to participate in any other conditions of the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with extensive stage small cell lung cancer treated with adebrelimab - SamplingMethod: Non-Probability Sample
Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer
Status: Recruiting

Predicting relapse and overall survival in potentially resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) patients remains challenging. It is now widely recognized that patients with detectable MRD have a worse prognosis than those with undetectable MRD. Therefore, investigators performed this prospective clinical trial to evaluate the predictive value of MRD with increased risk of relapse and improves prediction of outcome in potentially resectable Stage IIIA-IIIB NSCLC with neoadjuvant chemoimmunotherapy. In this study, investigators will pay more attention to the long-term follow-up time and dynamic monitoring of MRD. The predictive value of MRD with Disease-free survival (DFS) rate was observed as the primary endpoint. Besides that, the correlation of MRD with major pathologic response (MPR) rate, pathologic complete response (pCR) rate，event-free survival(EFS) rate and overall survival (OS) were observed as the second endpoints. Investigators hope it will provide a new insight for these potentially resectable Stage IIA-IIIB NSCLC with neoadjuvant chemoimmunotherapy.

Eligibility:
- EligibilityCriteria: Key Inclusion Criteria:  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 2. Have previously untreated and histological examination confirms resectable stage II-IIIA/IIIB non-small cell lung cancer (according to the 8th edition of the AJCC TNM staging criteria), and the pathological type of squamous cell carcinoma and non-squamous cell carcinoma needs to be distinguished, and EGFR, ALK, and ROS1 should be negative for non-squamous non-small cell lung cancer Adequate organ function and expected survival time ≥ 12 weeks; Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.  Key Exclusion Criteria:  Presence of mixed carcinoma component on histology. Patients with other active malignancies within 5 years prior to enrollment. Known active autoimmune diseases. Currently participate in an interventional clinical study treatment or have been treated with another drug or investigational device within 4 weeks prior to the first dose. Use of immunosuppressive agents within 14 days prior to the first dose of study treatment. Presence of other uncontrolled serious medical conditions. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patient initially diagnosed with resectable stage III-IIIA/IIIB non-small cell lung cancer t the First Hospital of Jilin University. - SamplingMethod: Non-Probability Sample
Transcutaneous Pulse Oximetry Brain Monitoring Study (US)
Status: Recruiting

This is a study of adult patients with a severe and sudden brain injury who have a drain placed in their brain to measure pressure. The purpose of the study is to monitor the pressure in the brain using a monitor placed on the forehead, and compare this to a drain placed in the brain.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  1. Adult brain-injured patients who have undergone external ventricular drain insertion for cerebrospinal fluid drainage and invasive intracranial pressure monitoring as part of standard medical care 2. Adult brain-injured patients who have undergone external ventricular drain insertion for cerebrospinal fluid drainage and invasive intracranial pressure monitoring that have concomitant continuous electroencephalography (EEG) monitoring as part of standard medical care  Exclusion Criteria:  1. Inability to obtain the brain pulse oximeter signal from at least one brain hemisphere due to interface issue such as severe agitation, head dressing, severe skin or bone trauma, or skull removal preventing brain pulse detection for the initial monitoring session.  a. Note: If unable to obtain brain pulse oximeter signal for subsequent monitoring sessions, the only the recordings that were obtained will be used for analysis  2. Hemodynamically unstable patients (defined as increasing vasopressors requirements) 3. Patients with unstable mechanical ventilation support defined as increasing fractional inspired oxygen (FiO2) requirements - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis
Status: Recruiting

The goal of this clinical trial is to compare the efficacy of hypertonic saline nebulization with adrenaline nebulization in the treatment of acute bronchiolitis in children. Main aim is to evaluate the following in both group of patients

Improvement in Wood-Downes clinical score (WDF score) in bronchiolitis
Length of Hospitalization

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  All children admitted in PICU with acute bronchiolitis  Exclusion Criteria:  children with co-exiting illnesses like  Congenital Heart Disease Immunodeficiency other Infectious disease like Meningitis, encephalitis, Pneumonia, TORCH Kidneys or liver problem Seizures - HealthyVolunteers: No - Gender: All - MinimumAge: 1 Month - MaximumAge: 2 Years - StdAgeList: Child
A Clinical Study to Compare Functional Outcomes After Surgery Using a Transverse or Longitudinal Surgical Incision in the Skin.
Status: Not yet recruiting

Trigger finger is a common pathology in the hand. Patients suffer from pain and depending on which tasks, patients have difficulty to perform them. Its treatment in initial and less serious phases includes conservative measures, but failure of these may require releasing the trigger finger with surgery. The surgical technique performed for trigger finger is the opening of the A1 pulley, the skin incisions used for this surgery are various (transverse, longitudinal, oblique). Trigger finger surgery presents good results in terms of resolution, but complications may also occur. The reason for this study is to assess whether there are functional differences using the Dash scale when we perform a transverse or longitudinal incision in trigger finger surgery.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients over 18 years of age. Clinical diagnosis of trigger finger grade II to IV.  Grade I (pre-trigger) Pain, history of entrapment, but not demonstrable on physical examination, tenderness over the A1 pulley.  Grade II (active) Demonstrable entrapment, but the patient can actively extend the finger.  Grade III (passive) Demonstrable entrapment, patient requires passive extension IIIA or inability to actively flex IIIB.  Grade IV (contracture) Demonstrable entrapment with fixed flexion contracture of the PIP.  Exclusion Criteria:  Thumb Polydigital Allergy to local anesthetics and/or vasoconstrictor agents. Previous surgery Patients who, in the researcher's opinion, are not good candidates for the study (e.g. inability to comply with the follow-up program, comorbidity, poor physical or mental health in general, drug or alcohol abuse problems...). - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 100 Years - StdAgeList: Adult, Older Adult
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Status: Recruiting

Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss medicine. The study will last for about 6 months.

Part B: The study will look at how CagriSema works on participants appetite and energy intake and will be compared with a ''dummy'' medicine. The study will also look at how participants brain works when participants take the medicine. Participants will either get CagriSema or ''dummy'' medicine.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or female Aged 18-65 years (both inclusive) at the time of signing informed consent Right-handed as evaluated by the Edinburgh Handedness Inventory Body weight less than or equal to 180 kilogram at screening  For Part A:  A score of 7 or less on the 16-item Disinhibition subscale of the Three Factor Eating Questionnaire Body mass index between 18.5 and 24.9 kilogram per meter square (both inclusive) at screening  For Part B:  A score of 8 or more on the 16-item Disinhibition subscale of the Three Factor Eating Questionnaire Body mass index equal to or above 27.0 kilogram per meter square. Overweight should be due to excess adipose tissue, as judged by the investigator  Exclusion Criteria:  Contraindication for magnetic resonance scanning  For Part B:  Glycated haemoglobin greater than or equal to 6.5 % (48 millimoles per mole) at screening History of type 1 or type 2 diabetes mellitus - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Fractional Carbon Dioxide Laser: A Novel Therapeutic Option for Lichen Simplex Chronicus
Status: Not yet recruiting

The goal of this randomized control trial is to compare the use of fractional carbon dioxide (Co2) laser to topical corticosteroids to treat lichen simplex chronicus (LSC) patients presenting to Dermatology outpatient clinic, Faculty of Medicine, Cairo University.

Participants will:

Be assessed clinically by doctor
Biopsies will be taken from them by doctor
Receive treatment as laser or topical steroids or both
Fill in depression questionnaire.

Researchers will divide and compare groups as follows:

Sixty patients will be divided randomly through closed envelop technique into 2 groups (Group A and B) each of 30 patients. Group A will be subdivided into 2 groups (1 and 2). All LSC lesions will be treated in any patient having multiple lesions.

Group 1 - A: Patients will receive 3 monthly laser sessions, in addition to the use of topical emollients only once daily in between the sessions.
Group 2 - A: Patients will receive 3 monthly laser sessions, in addition to topical steroids twice daily and topical emollient once daily in between the sessions.
Group B: Patients will be prescribed topical steroids twice daily and topical emollient once daily for 3 months.

to see if:

Pruritus severity scale.
Scaling, erythema, lichenification excoriation scores
Visual analogue scale.
Investigator's Global Assessment.
Itching mediators (Interleukin-31, Nerve Growth Factor and Substance P assays (itching mediators)
Depression

improve more in which group of patients after treatment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients with LSC with no underlying dermatological disease, not on topical or systemic treatment for at least 4 weeks prior to study.  Exclusion Criteria:  Pregnant and lactating females. Patients who are diagnosed with any systemic disease that can result in generalized pruritus (e.g. hepatic, renal, uncontrolled diabetes mellitus, thyroid,….etc ) from history. Patients with contraindications to laser e.g., keloidal tendency, post inflammatory hyperpigmentation (PIH). Patients with dermatological disease (e.g. psoriasis, atopic dermatitis, ….etc) - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Linguistic and Clinical Validation of the Arabic Version of Acute Cystitis Symptom Score (ACCS)
Status: Recruiting

The goal of this prospective observational study is to provide an Arabic translation of the Acute Cystitis Symptom Score (ACSS) and to test the linguistic validity and clinical reliability of the translated Arabic version of ACCS (Arabic-ACCS) in Arabic-speaking women older than 18 years of age diagnosed with uncomplicated cystitis.

The main questions it aims to answer are:

Do the questions of the Arabic-ACSS have sufficient clarity?
Can the Arabic-ACCS serve its purpose in identifying the presence of uncomplicated cystitis in Arabic-speaking women? The participant will be asked to fill out the Arabic-ACCS questionnaire at the time of diagnosis. The participants will be asked to fill out the second part of the Arabic-ACCS questionnaire 5-10 days later after receiving the appropriate treatment according to the local health policy as prescribed by the treating physician.

Researchers will compare the results from the patients who filled out the first part of the questionnaire with the results of a comparable group of women who were presented with complaints unrelated to the lower urinary tract.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  women. presented to the urology or gynecology and obstetrics outpatient clinics. having the diagnosis of uncomplicated cystitis.  Exclusion Criteria:  pregnancy. urethral catheterization. anatomical abnormality of the urinary tract. Neurologic abnormality that affects bladder function. urinary tract stones. - Gender: Female - GenderBased: Yes - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Women presented to the urology or gynecology and obstetrics outpatient clinics at Alkindy Teaching Hospital and Al-Elwiya Maternity Teaching Hospital having the diagnosis of uncomplicated cystitis will serve as the case group.  In addition, a control group of women attending the same clinics who are complaining of conditions unlikely to affect the symptoms of the lower urinary tract will be recruited as a control group - SamplingMethod: Non-Probability Sample
Use of a Virtual Reality Cognitive Stimulation Programme for Breast Cancer Patients Wishing to Restart or Maintain a Professional Activity
Status: Not yet recruiting

The study concerns patients who have been treated for breast cancer, have cognitive problems and are planning to return to work or are currently working and wish to begin cognitive rehabilitation.

Patients will follow the Virtual Reality program developed for the study, during the cognitive rehabilitation usually proposed in the establishment, at the rate of a weekly session of 10-15 minute for 6 weeks.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients >18 years of age Patient with breast cancer for whom adjuvant chemotherapy has been administered; maintenance treatments (e.g. Trastuzumab, hormone therapy) are eligible, Maximum 2 years after completion of adjuvant treatment, Patients who have cognitive complaints at inclusion (answer yes to the question: 'Since your cancer treatment, have you had any difficulties with memory, concentration, etc.?) Patients planning to return to work or who have returned to work in the past year, Signature of informed consent prior to any specific procedure relating to the study, Patient affiliated to a social security system.  Exclusion Criteria:  Patients suffering from illnesses or conditions that impair their ability to understand, follow and/or comply with study procedures, Patients with personality disorders and/or psychiatric pathology, Patients deprived of their liberty or placed under the authority of a guardian, Pregnant women - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
Status: Recruiting

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered to participants with non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Eastern Cooperative Oncology Group performance status of 0 or 1 Histological or cytological diagnosis of Stage IIB, IIIA, and select IIIB NSCLC of either non-squamous or squamous histology Participants must have had complete resection of NSCLC Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy Participants must have recovered adequately from surgery and from adjuvant chemotherapy Tumor cell PD-L1 expression at >/= 1% Adequate hematologic and end-organ function.  Exclusion Criteria:  Any history of prior NSCLC within the last 5 years Any evidence of residual disease or disease recurrence following surgical resection of NSCLC, or during or following adjuvant chemotherapy NSCLC known to have mutation in the EGFR gene or an ALK fusion oncogene - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Chronic Kidney Disease Patient in Chronic Myloied Leukemia
Status: Not yet recruiting

To study the Prevalence ,Characteristics and outcome of CKD in patiants with chronic myeloid leukemia .

Eligibility:
- EligibilityCriteria: Inclusion Criteria:1_ Chronic myloid leukemia patiants who diagonised by biopsy , 2_ CBC.  -  Exclusion : 1_pts known to have CKD before diagnosed of CML. 2- known Diabetic pts 3-imaging suggestive CKD etiology rather than CML effect eg.PKD,renal stones,chronic pyelonephritis - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult - StudyPopulation: all sexes , adult , not diabetic , not known CKD before diagnosed of CML - SamplingMethod: Non-Probability Sample
Perimetry Based on Eye-movements in Patients With (Supra)Sellar Tumors
Status: Not yet recruiting

The purpose of this study is to assess wether the SONDA visual field test is suitable for patients with a supra sellar tumour.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Diagnosed with a (supra)sellar tumor Visual field loss based on the most recent SAP; False positive rate <15%; fixation losses <20% Informed written consent  Exclusion Criteria:  Neurological disorders Eye disease not related to a (supra)sellar tumor - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with a (supra)sellar tumour and healthy controls - SamplingMethod: Non-Probability Sample
Smart Life Smart Living Intercontinental - Medical Students' Cohort
Status: Not yet recruiting

The question of the well-being, quality of life and mental health of care students is unanimously considered to be a central issue among young adults. According to the French Ministry of Higher Education and Research, there will be 194,752 care students in France in 2021-2022. The quality of life and well-being of health students can be affected at several levels. The first is mental health. In France, the mental health of these students has deteriorated considerably in recent years. According to a 2017 survey of 21,768 French medical students, 66% of them had an anxiety disorder and 27% a depressive syndrome. In addition, a number of risk factors have been identified for the mental health of health students.

The aim of the study is to carry out a longitudinal evaluation of the mental health status of care students during their university studies in France through anxiety, depression and perceived stress.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  students who are regularly enrolled in healthcare courses at a French university  Exclusion Criteria:  Age under 18 - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study concerns students over the age of 18 who are regularly enrolled in healthcare courses at a French university.  The study involves longitudinal monitoring of the state of health of the specific population of students in care courses, from their entry into university studies (first year) until their final year of study, i.e. from 5 to 13 years depending on the course and the different universities. - SamplingMethod: Non-Probability Sample